Oncolytic viruses for potential osteosarcoma therapy

Pooja Hingorani, Valerie Sampson, Christina K Lettieri, E. Anders Kolb

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Since the first anecdotal reports of dramatic tumor responses following a viral infection in early 1900s, the field of oncolytic virotherapy has evolved at a rapid pace finally making its way into clinical trials. A large number of both wild-type and genetically altered viruses with a preferential replication-competency for tumor cells have been studied in tissue cultures, animal models and in humans, with an ever increasing repertoire of new viruses being added to this pool. Although oncolytic viruses have caused dramatic antitumor responses in cell cultures and mouse models, their clinical effects in humans have been modest. Therefore, the current research is focused on understanding the mechanisms by which viruses kill tumor cells, the barriers to successful viral delivery and penetration into tumor cells, the role of the immune system in viral oncolysis and generating stronger target specifi c and replication competent viruses. Osteosarcoma is a challenging malignancy to identify novel targets for therapy due to its complex genetic make-up. Oncolytic virotherapy may be a promising approach as a novel therapeutic, not dependent on consistent expression of a single target. In this review we summarize the supportive evidence and rationale for use of viral oncolysis in osteosarcoma along with the specifi c challenges it may face.

Original languageEnglish (US)
Pages (from-to)259-283
Number of pages25
JournalAdvances in experimental medicine and biology
Volume804
DOIs
StatePublished - Jan 1 2014

Fingerprint

Oncolytic Viruses
Osteosarcoma
Viruses
Oncolytic Virotherapy
Tumors
Cells
Neoplasms
Oncogenic Viruses
Virus Diseases
Therapeutics
Virus Replication
Tissue culture
Immune system
Immune System
Cell culture
Animal Models
Cell Culture Techniques
Clinical Trials
Animals
Research

Keywords

  • Cancer stem cells
  • DNA virus
  • Oncolytic viruses
  • Osteosarcoma
  • RNA virus
  • Replication-competent
  • Virotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Oncolytic viruses for potential osteosarcoma therapy. / Hingorani, Pooja; Sampson, Valerie; Lettieri, Christina K; Kolb, E. Anders.

In: Advances in experimental medicine and biology, Vol. 804, 01.01.2014, p. 259-283.

Research output: Contribution to journalArticle

Hingorani, Pooja ; Sampson, Valerie ; Lettieri, Christina K ; Kolb, E. Anders. / Oncolytic viruses for potential osteosarcoma therapy. In: Advances in experimental medicine and biology. 2014 ; Vol. 804. pp. 259-283.
@article{87538bf007d94cb9bfbf61e85049a67d,
title = "Oncolytic viruses for potential osteosarcoma therapy",
abstract = "Since the first anecdotal reports of dramatic tumor responses following a viral infection in early 1900s, the field of oncolytic virotherapy has evolved at a rapid pace finally making its way into clinical trials. A large number of both wild-type and genetically altered viruses with a preferential replication-competency for tumor cells have been studied in tissue cultures, animal models and in humans, with an ever increasing repertoire of new viruses being added to this pool. Although oncolytic viruses have caused dramatic antitumor responses in cell cultures and mouse models, their clinical effects in humans have been modest. Therefore, the current research is focused on understanding the mechanisms by which viruses kill tumor cells, the barriers to successful viral delivery and penetration into tumor cells, the role of the immune system in viral oncolysis and generating stronger target specifi c and replication competent viruses. Osteosarcoma is a challenging malignancy to identify novel targets for therapy due to its complex genetic make-up. Oncolytic virotherapy may be a promising approach as a novel therapeutic, not dependent on consistent expression of a single target. In this review we summarize the supportive evidence and rationale for use of viral oncolysis in osteosarcoma along with the specifi c challenges it may face.",
keywords = "Cancer stem cells, DNA virus, Oncolytic viruses, Osteosarcoma, RNA virus, Replication-competent, Virotherapy",
author = "Pooja Hingorani and Valerie Sampson and Lettieri, {Christina K} and Kolb, {E. Anders}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-319-04843-7_14",
language = "English (US)",
volume = "804",
pages = "259--283",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-275X",
publisher = "Springer New York",

}

TY - JOUR

T1 - Oncolytic viruses for potential osteosarcoma therapy

AU - Hingorani, Pooja

AU - Sampson, Valerie

AU - Lettieri, Christina K

AU - Kolb, E. Anders

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Since the first anecdotal reports of dramatic tumor responses following a viral infection in early 1900s, the field of oncolytic virotherapy has evolved at a rapid pace finally making its way into clinical trials. A large number of both wild-type and genetically altered viruses with a preferential replication-competency for tumor cells have been studied in tissue cultures, animal models and in humans, with an ever increasing repertoire of new viruses being added to this pool. Although oncolytic viruses have caused dramatic antitumor responses in cell cultures and mouse models, their clinical effects in humans have been modest. Therefore, the current research is focused on understanding the mechanisms by which viruses kill tumor cells, the barriers to successful viral delivery and penetration into tumor cells, the role of the immune system in viral oncolysis and generating stronger target specifi c and replication competent viruses. Osteosarcoma is a challenging malignancy to identify novel targets for therapy due to its complex genetic make-up. Oncolytic virotherapy may be a promising approach as a novel therapeutic, not dependent on consistent expression of a single target. In this review we summarize the supportive evidence and rationale for use of viral oncolysis in osteosarcoma along with the specifi c challenges it may face.

AB - Since the first anecdotal reports of dramatic tumor responses following a viral infection in early 1900s, the field of oncolytic virotherapy has evolved at a rapid pace finally making its way into clinical trials. A large number of both wild-type and genetically altered viruses with a preferential replication-competency for tumor cells have been studied in tissue cultures, animal models and in humans, with an ever increasing repertoire of new viruses being added to this pool. Although oncolytic viruses have caused dramatic antitumor responses in cell cultures and mouse models, their clinical effects in humans have been modest. Therefore, the current research is focused on understanding the mechanisms by which viruses kill tumor cells, the barriers to successful viral delivery and penetration into tumor cells, the role of the immune system in viral oncolysis and generating stronger target specifi c and replication competent viruses. Osteosarcoma is a challenging malignancy to identify novel targets for therapy due to its complex genetic make-up. Oncolytic virotherapy may be a promising approach as a novel therapeutic, not dependent on consistent expression of a single target. In this review we summarize the supportive evidence and rationale for use of viral oncolysis in osteosarcoma along with the specifi c challenges it may face.

KW - Cancer stem cells

KW - DNA virus

KW - Oncolytic viruses

KW - Osteosarcoma

KW - RNA virus

KW - Replication-competent

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=84907173927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907173927&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-04843-7_14

DO - 10.1007/978-3-319-04843-7_14

M3 - Article

VL - 804

SP - 259

EP - 283

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-275X

ER -